JAMA Internal Medicine

APRIL 3, 2022

This randomized clinical trial investigates whether daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is safe and noninferior compared with darbepoetin alfa in treating anemia of chronic kidney disease in incident dialysis patients.

Clinical Trials 72

Clinical Trials Clinical Trials Trials 72

The Pharma Data

APRIL 3, 2022

Treatment with mavacamten showed sustained improvement in left ventricular outflow tract (LVOT) gradients, New York Heart Association (NYHA) Class and N-terminal pro brain natriuretic peptide (NT-proBNP) levels. At 48 and 84 Weeks, Mavacamten safety was consistent with that seen in the EXPLORER-HCM study. Interim results were presented as a late-breaking clinical trial at the American College of Cardiology’s 71 st Annual Scientific Session.

Clinical Trials 52

Clinical Trials Clinical Trials Compliance Trials 52

JAMA Internal Medicine

APRIL 3, 2022

This JAMA Internal Medicine Patient Page describes the use and accuracy of, as well as harms and concerns associated with, at-home genetic tests.

Genetics 75

Genetics Medicine 75

Drug Patent Watch

APRIL 3, 2022

This chart shows the pharmaceutical companies with the most patents in Brazil. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Brazil? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98

Drugs 98

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

FDA Law Blog

APRIL 3, 2022

By Larry K. Houck — Effective April 1, 2022, California Board of Pharmacy (“BOP”) regulations no longer require reporting every single missing tablet or dosage form. Instead, the amended loss regulations establish thresholds which will reduce the number of reports received by the California BOP, and in our opinion, creates a more meaningful and substantive reporting system.

Pharmacy 52

Pharmacy Regulation Drugs Licensing 52